Xiaoming Yi
Overview
Explore the profile of Xiaoming Yi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
227
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang B, Xie T, Li H, Yi X, Ding M, Xue S, et al.
BMC Cancer
. 2024 Aug;
24(1):1011.
PMID: 39143525
Background: Renal cell carcinoma (RCC) is a type of cancer that can develop at any point in adulthood, spanning the range of age-related changes that occur in the body. However,...
2.
Fu D, Shi X, Yi X, Wu D, He H, Zhou W, et al.
BMC Urol
. 2024 Jul;
24(1):147.
PMID: 39014364
Background: Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has been confirmed to play oncogenic role in many cancers. However, the role and mechanism of IGF2BP2 in bladder cancer (BCa)...
3.
Wu D, Zhou Y, Shi X, Yi X, Sheng Z, Fan L, et al.
Toxicol Appl Pharmacol
. 2024 May;
487:116975.
PMID: 38762191
Kidney renal clear cell carcinoma (KIRC) is a highly immune-infiltrated kidney cancer with the highest mortality rate and the greatest potential for invasion and metastasis. Solute carrier family 11 member1...
4.
Zhou Y, Gu Y, Tang C, Dong J, Xu S, Sheng Z, et al.
Front Oncol
. 2023 Nov;
13:1239405.
PMID: 37941564
Introduction: Metastatic renal cell carcinoma (mRCC) with sarcomatoid features has a poor prognosis. Cytoreductive radical nephrectomy (CRN) can improve prognosis, but patient selection is unclear. This study aimed to develop...
5.
Qu L, Chen H, Chen Q, Ge S, Jiang A, Yu N, et al.
MedComm (2020)
. 2023 Jul;
4(4):e300.
PMID: 37484972
There is significant variability with respect to the prognosis of nonmetastatic clear cell renal cell carcinoma (ccRCC) patients with venous tumor thrombus (VTT). By applying multiregion whole-exome sequencing on normal-tumor-thrombus-metastasis...
6.
Shen T, Miao S, Zhou Y, Yi X, Xue S, Du B, et al.
Cell Commun Signal
. 2022 Sep;
20(1):152.
PMID: 36153596
Background: Tumorigenic phenotype of M2 tumor-associated macrophages promote tumor progression in response to exosomes cues imposed by tumor cells. However, the effect and underlying mechanisms of clear cell renal cell...
7.
Tang C, Zhou Y, Ge S, Yi X, Lv H, Zhou W
Front Oncol
. 2021 Oct;
11:727222.
PMID: 34595117
Objective: To investigate the exact age-adjusted incidence (AAI), clinical characteristics, and survival data of collecting duct carcinoma of the kidney (CDCK) recorded in the Surveillance, Epidemiology, and End Results (SEER)...
8.
Zhao T, Zhou Y, Wang Q, Yi X, Ge S, He H, et al.
Int J Oncol
. 2021 May;
59(1).
PMID: 34036385
Sunitinib is widely used as a first‑line treatment for advanced renal cell carcinoma (RCC). However, a number of patients with RCC who receive sunitinib develop drug resistance; and the biological...
9.
Wang Y, Wu J, Chen H, Yang Y, Xiao C, Yi X, et al.
Sci Adv
. 2021 Feb;
7(5).
PMID: 33571129
Cancer stem cells (CSCs) are involved in tumorigenesis, recurrence, and therapy resistance. To identify critical regulators of sarcoma CSCs, we performed a reporter-based genome-wide CRISPR-Cas9 screen and uncovered Kruppel-like factor...
10.
Du B, Zhou Y, Yi X, Zhao T, Tang C, Shen T, et al.
Front Oncol
. 2020 Oct;
10:1770.
PMID: 33014871
Clear cell renal cell carcinoma (ccRCC) is one of the most common tumors in the urinary system. Progression in immunotherapy has provided novel options for the ccRCC treatment. However, the...